Comments

Comments to MACPAC urging an exemption from the Medicaid community engagement requirement for People Living with HIV

As you develop your principles and policy options we urge MACPAC to recommend an explicit exemption for all people living with HIV from the community engagement requirement mandated by Public Law 119-21, also known as the One Big Beautiful Bill Act. People with HIV are living with a lifelong serious and complex medical condition and have special medical needs: they cannot stay healthy without continuous access to their lifesaving HIV treatment. Any gap in treatment risks serious health consequences, including failure of viral suppression and the risk of onward transmission. Longer treatment gaps are potentially disabling, allowing progression to AIDS, after which life expectancy is limited.

read more

Comments to Oregon PDAB on draft 2026 drug review preliminary list

Affordability reviews of HIV medications are unlikely to fully capture the complexity and interdependence of safety net programs, which not only ensure affordability for patients but also sustain the broader HIV care infrastructure. While we recognize the Board’s current position to not seek upper payment limit authority, reviewing medications like Biktarvy, Descovy, and Emtricitabine-Tenofovir based on list price alone (despite their actual affordability for the vast majority of patients) could have significant unintended consequences. Such reviews risk creating systemic uncertainty for manufacturers, healthcare providers, and safety net programs that rely heavily on drug rebates to fund essential wraparound services. Ultimately, this instability could undermine the delicate balance required for continued investment in the transformative advancements our community relies on, including longer-acting treatments, preventive therapies, vaccines, and the pursuit of an eventual cure.

read more

Coverage of preventive services is a legal requirement

Carl Schmid commented on the JAMA Viewpoint piece “Subscription-Based Pricing for Lenacapavir—Learning From Hepatitis C and Cabotegravir,” taking issue with the authors’ dismissal of advocates focus on insurer’s responsibility to follow the law and cover PrEP as a no cost preventive service and offering comments on the hepatitis C subscription model and the need for a comprehensive PrEP program to increase uptake.

read more

Support for improving Ryan White HIV/AIDS Program Part A and B formula awards

We are in strong support of HAB’s proposal included in the Federal Register on November 10, 2025, to update the funding formulas used by the Ryan White HIV/AIDS Program (RWHAP) for allocating Part A and Part B funding. This welcome change is long overdue and will increase equity in the distribution of funding and better match the level of funding with the number of RWHAP clients residing in a jurisdiction.

read more

Pin It on Pinterest